Centers | ||
Edinburgh Drug Discovery | EU-OPENSCREEN | Therapeutic Accelerator Program (TAP) |
Based within the world-leading University of Edinburgh Medical School, Edinburgh Drug Discovery has a track record in successfully translating drug discovery projects from target identification through to clinical evaluation. Key areas of... |
EU-OPENSCREEN is a multinational, not-for-profit initiative, which
integrates high-capacity screening platforms and chemistry groups across
Europe. The aim of this initiative is to support individual scientists
interested in chemical biology... |
Test |
Partnerships |
Events |
Jobs |
Evotec and Yale University form Open Innovation AllianceEvotec and Yale intend to leverage first rate science performed at Yale University together with Evotec's drug discovery infrastructure and expertise into highly innovative discovery approaches in diseases of high unmet medical need. Initially,... View all Cerecor Partners with Johns Hopkins Brain Science Institute to Treat SchizophreniaCerecor a Baltimore based company has taken an option with Johns Hopkins University to license D-Amino Acid Oxidase inhibitors (DAAO) to treat Schizophrenia. The DAAO inhibitor molecules are currently being developed by researchers at the Johns... View all UCSF And Genentech to Develop Drugs to Treat Neurodegenerative DiseasesUniversity of California, San Francisco (UCSF) and Genetech have entered into a research collaboration to develop drugs to treat neurodegenerative diseases. Genetech will be providing funding to researchers at UCSF Small Molecule Discovery Center... View all |
No EVENTS for listing |
No Job Posts |


